Everything Jim Cramer said about the stock market on 'Mad Money,' including coronavirus sell-off, Domino's Pizza CEO, Vertex
watch now

CNBC's Jim Cramer broke down Thursday's sell-off and explained why he thinks the coronavirus outbreak will continue to be a thorn in the market. The "Mad Money" host checked in with Domino's Pizza CEO Ritch Allison after the chain reported a domineering fourth-quarter amid a tight delivery market. Later in the show Cramer broke down why investors may want to buy the dip in Vertex Pharmaceuticals.

More sell-offs to come

Healthcare workers are working in protective gear at the National Medical Center on February 20, 2020 in Seoul, South Korea. Jong-Hyun Kim | Anadolu Agency | Getty Images

Domino's Pizza dominates in fourth quarter

An employee moves a pizza to an oven at a Domino's Pizza Inc. restaurant in Chantilly, Virginia. Andrew Harrer | Bloomberg | Getty Images

Carryout has become a bright spot for Domino's Pizza as the restaurant chain battles in a tough, low-margin food delivery environment, CEO Ritch Allison told Cramer. Shares of the Ann Arbor, Michigan-based pizza franchise popped almost 26% during the trading day on a strong fourth-quarter report that smashed Wall Street estimates. "While most of the industry is running headlong into delivery, which is inherently a more profitable channel to serve, we're working hard to hold serve on that delivery side of the business while really growing that carryout channel," Allison said in a "Mad Money" interview. Carryout "is going to be an important part of the profit equation going forward."

Buy the biotech dip

Jeffrey Leiden, M.D., Ph.D., Chairman, President and Chief Executive Officer of Vertex Pharmaceuticals, poses for a portrait at the Vertex Pharmaceuticals headquarters in Boston on Nov. 28, 2017. Dina Rudick | The Boston Globe | Getty Images

The market gave investors an opportunity to buy position in Vertex Pharmaceuticals as drug stocks traded lower the day after the Nevada Democratic debate, Cramer said. "Vertex Pharma got dinged today, and I think this is a very buyable dip in what's widely considered to be the hottest biotech story of the year," the host said, adding the company "accomplished something that was unthinkable not too long ago, a near-triumph over the scourge that is cystic fibrosis."

Cramer's lightning round